EASD 2026 | Ecnoglutide Demonstrates Favorable Safety Profile in Adolescents with Obesity
HANGZHOU, China, Sept. 30, 2026 /PRNewswire/ -- At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind") today announced that its Phase 1b randomized, double-blind,...
Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative therapies for metabolic diseases, today announced...